Jynneos

— THERAPEUTIC CATEGORIES —
  • Vaccines
PAGE CONTENTS
  • Jump to Section
  • Generic Name & Formulations
  • Indications
  • Dosage and Administration
  • Contraindications
  • Boxed Warnings
  • Warnings/Precautions
  • Pharmacokinetics
  • Interactions
  • Adverse Reactions
  • Clinical Trials
  • Note
  • Patient Counseling

    • Jynneos Generic Name & Formulations

    Legal Class

    Rx

    General Description

    Smallpox and Monkeypox vaccine, live, non-replicating; contains 0.5–3.95×108 infectious units of MVA-BN live virus; per 0.5mL dose; susp for SC inj; preservative-free.

    How Supplied

    Single-dose vials—10, 20

    Storage

    • Keep frozen at -25°C to -15°C (-13°F to +5°F). Store in the original package to protect from light. Do not refreeze a vial once it has been thawed. Once thawed, the vaccine may be kept at +2°C to +8°C (+36°F to +46°F) for 4 weeks. Do not use the vaccine after the expiration date shown on the vial label.

    Manufacturer

    Bavarian Nordic, Inc.

    Generic Availability

    NO

    Mechanism of Action

    Jynneos is an attenuated, live, non-replicating smallpox and monkeypox vaccine that elicits humoral and cellular immune responses to orthopoxviruses. Vaccinia neutralizing antibody responses in humans were evaluated to establish the effectiveness of Jynneos for prevention of smallpox and monkeypox.

    Jynneos Indications

    Indications

    Prevention of smallpox and monkeypox disease in adults determined to be at high risk for smallpox or monkeypox infection.

    Jynneos Dosage and Administration

    Adult

    Give by SC inj (preferably into deltoid). ≥18yrs: 2 doses (0.5mL each) given 4 weeks apart.

    Children

    <18yrs: not established.

    Jynneos Contraindications

    Not Applicable

    Jynneos Boxed Warnings

    Not Applicable

    Jynneos Warnings/Precautions

    Warnings/Precautions

    Have appropriate medical treatment available to manage possible anaphylactic reactions. Immunocompromised. Vaccination may not protect all recipients. Pregnancy. Nursing mothers.

    Pregnancy Considerations

    Risk Summary 

    • Available human data on Jynneos administered to pregnant women are insufficient to inform vaccine-associated risks in pregnancy.

    Nursing Mother Considerations

    Risk Summary 

    • It is not known whether Jynneos is excreted in human milk.

    • Consider the development and health benefits of breastfeeding along with the mother’s clinical need for Jynneos and any potential adverse effects on the breastfed child from Jynneos or from the underlying maternal condition. 

    Pediatric Considerations

    • Safety and effectiveness have not been established in individuals less than 18 years of age.

     

    Geriatric Considerations

    • Clinical studies did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.

    Jynneos Pharmacokinetics

    See Literature

    Jynneos Interactions

    Not Applicable

    Jynneos Adverse Reactions

    Adverse Reactions

    Inj site reactions (eg, pain, swelling, redness, induration, itching), muscle pain, headache, fatigue, nausea, chills; severe allergic reactions.

    Jynneos Clinical Trials

    Clinical Trials

    Vaccine Effectiveness

    • Vaccine effectiveness against smallpox was inferred by comparing the immunogenicity of Jynneos to a licensed smallpox vaccine (ACAM2000) based on a Plaque Reduction Neutralization Test (PRNT) using the Western Reserve strain of vaccinia virus and was supported by efficacy data from animal challenge studies. 

    • Vaccine effectiveness against monkeypox was inferred from the immunogenicity of Jynneos in a clinical study and from efficacy data from animal challenge studies. 

    Immunogenicity – (Study 7)

    • The randomized, open-label study was conducted at US military facilities in South Korea. The study compared the immunogenicity of Jynneos to ACAM2000 in healthy smallpox vaccine-naïve 433 adults 18 through 42 years of age. Patients were randomly assigned 1:1 to receive 2 doses of Jynneos (28 days apart) or 1 dose of ACAM2000.

    • The primary immunogenicity endpoint was geometric mean titer (GMT) of vaccinia neutralizing antibodies assessed by PRNT at “peak visits” defined as two weeks after the second dose of JYNNEOS and four weeks after the single dose of ACAM2000.

    • The GMT of vaccinia neutralizing antibodies assessed post-vaccination at “peak visits” for Jynneos was 152.8 vs 84.4 for ACAM2000.

    • The PRNT GMTs at two and four weeks after the first dose of Jynneos (prior to the second dose), were 23.4 (95% CI: 20.5, 26.7) and 23.5 (95% CI: 20.6, 26.9), respectively. The PRNT GMT at two weeks after the single dose of ACAM2000 was 23.7 (95% CI: 20.9, 26.8).

    Jynneos Note

    Not Applicable

    Jynneos Patient Counseling

    Patient Counseling

    • Inform vaccine recipient of the potential benefits and risks of vaccination with Jynneos. 

    • Inform vaccine recipient of the importance of completing the two dose vaccination series. 

    • Advise vaccine recipient to report any adverse events to their healthcare provider or to the Vaccine Adverse Event Reporting System at 1-800-822-7967 and www.vaers.hhs.gov.

    • Latest News Your top articles for Friday

    • Haymarket Medical NetworkTop Picks

    • Loading...

      Continuing Medical Education (CME/CE) Courses

      Show More